DESCRIPTION
Aglip™ is Alogliptin preparation which is a dipeptidyl peptidase (DPP)-4 inhibitor thus inhibits DPP-4 and activate GLP-1 to increase insulin production and decrease glucagon secration. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity.
Find More Products
Featured Product
